Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-30

Clinical Trial Update: A Multicenter Assessment of ALD403 in Chronic Migraine [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial assessing ALD403 for chronic migraine has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALD403

Snippet

Sponsor: Alder Biopharmaceuticals, Inc. | Conditions: Migraine Disorders | Phase 2 | Status: COMPLETED | Results posted: 2020-03-30